It is common that patients with mitochondrial diseases and type 2 diabetes need insulin therapy, while in non-insulin-dependent patients sulphonylureas are the first-choice pharmacological treatment (3, 115, 116, 119). This evidence concerns the gene INS and type 2 diabetes mellitus.